Vivimed Labs soars on acquiring US FDA approved formulation manufacturing facility

01 Aug 2013 Evaluate

Vivimed Labs is currently trading at Rs. 106.10, up by 5.05 points or 5.00% from its previous closing of Rs. 101.05 on the BSE.

The scrip opened at Rs. 96.00 and has touched a high and low of Rs. 106.10 and Rs. 96.00 respectively. So far 197627 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 403.65 on 10-Sep-2012 and a 52 week low of Rs. 101.05 on 31-Jul-2013.

Last one week high and low of the scrip stood at Rs. 216.50 and Rs. 101.05 respectively. The current market cap of the company is Rs. 170.41 crore.

The promoters holding in the company stood at 39.83% while Institutions and Non-Institutions held 29.87% and 30.30% respectively.

Vivimed Labs has acquired Actavis Pharma Manufacturing’s (APMPL) solid oral dosage facility in Alathur, Tamil Nadu for Rs 122 crore. The facility, which Vivimed acquired from APMPL’s parent Actavis Holding Asia BV, has already received the US Food and Drug Administration (US FDA) approval. 

Along with the facility, the company has also acquired two commercially valuable and marketable Abbreviated New Drug Applications (ANDAs) which will allow the company to generate additional revenues.

Vivimed Labs’s manufacturing unit is located at Bidar, Karnataka, where it was originally engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs) and bulk drugs like Ibuprofen etc.

Vivimed Labs Share Price

5.75 0.00 (0.00%)
31-Jul-2023 18:02 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1814.75
Dr. Reddys Lab 1341.60
Cipla 1476.45
Lupin 2168.25
Zydus Lifesciences 972.30
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.